^
    Back
    Association details:
    Biomarker:PIK3CA P449T
    Cancer:Colorectal Cancer
    Drug:Kisqali (ribociclib) (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Anticancer Res
    Title:

    Synergistic and Antagonistic Antiproliferative Effects of Ribociclib (Lee011) and Irinotecan (SN38) on Colorectal Cancer Cells

    Published date:
    05/05/2023
    Excerpt:
    The combination of LEE011 and SN38 elicited a synergistic antiproliferative effect on HT-29 (PIK3CAP449T mutation) cells, and an antagonistic antiproliferative effect on SW480 (KRASG12V mutation) cells….The effects of the combination of LEE011 and conventional chemotherapy drugs on CRC depend on the chemotherapy drug and the specific gene mutation harbored by tumor cells.
    Secondary therapy:
    irinotecan
    DOI:
    10.21873/anticanres.16353